Health outcomes among patients diagnosed with schizophrenia in the US veterans health administration population who transitioned from once-monthly to once-every-3-month Paliperidone Palmitate: an observational retrospective analysis

Abstract

There is limited literature on treatment patterns, healthcare resource utilization (HRU), and costs among patients who transition from once-monthly paliperidone palmitate (PP1M) to once-every-3-month paliperidone palmitate (PP3M) in a real-world setting. Hence, this study compared treatment patterns, HRU, and costs 12-month pre- and post-PP3M transition among Veteran’s Health Administration (VHA) patients with schizophrenia.